Steris PLC (STE) Stake Increased by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. lifted its stake in shares of Steris PLC (NYSE:STE) by 13.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,086 shares of the medical equipment provider’s stock after buying an additional 500 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Steris were worth $437,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in STE. Oregon Public Employees Retirement Fund boosted its holdings in Steris by 10,585.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,572,743 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 3,539,306 shares during the period. WCM Investment Management CA boosted its holdings in Steris by 122.3% in the third quarter. WCM Investment Management CA now owns 2,278,403 shares of the medical equipment provider’s stock worth $260,650,000 after purchasing an additional 1,253,653 shares during the period. Federated Investors Inc. PA boosted its holdings in Steris by 2,546.2% in the third quarter. Federated Investors Inc. PA now owns 868,434 shares of the medical equipment provider’s stock worth $99,348,000 after purchasing an additional 835,616 shares during the period. Villere ST Denis J & Co. LLC acquired a new position in Steris in the fourth quarter worth $63,124,000. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in Steris by 100.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 1,127,301 shares of the medical equipment provider’s stock worth $123,673,000 after purchasing an additional 563,939 shares during the period. 88.65% of the stock is owned by hedge funds and other institutional investors.

NYSE STE traded down $0.13 on Wednesday, hitting $122.38. 34,999 shares of the company were exchanged, compared to its average volume of 443,251. The company has a current ratio of 2.56, a quick ratio of 1.99 and a debt-to-equity ratio of 0.40. The company has a market cap of $10.34 billion, a PE ratio of 29.49 and a beta of 1.04. Steris PLC has a twelve month low of $88.81 and a twelve month high of $123.53.



Steris (NYSE:STE) last posted its quarterly earnings data on Monday, February 11th. The medical equipment provider reported $1.26 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.26. The firm had revenue of $696.24 million for the quarter, compared to the consensus estimate of $687.90 million. Steris had a return on equity of 12.50% and a net margin of 9.85%. Research analysts forecast that Steris PLC will post 4.78 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 21st. Shareholders of record on Wednesday, February 27th will be issued a dividend of $0.34 per share. The ex-dividend date is Tuesday, February 26th. This represents a $1.36 annualized dividend and a yield of 1.11%. Steris’s payout ratio is presently 32.77%.

In other Steris news, VP John Adam Zangerle sold 3,000 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $115.00, for a total transaction of $345,000.00. Following the sale, the vice president now owns 33,796 shares in the company, valued at approximately $3,886,540. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.38% of the stock is currently owned by insiders.

STE has been the subject of several analyst reports. Stephens reissued a “buy” rating and set a $135.00 price target on shares of Steris in a report on Thursday, February 14th. KeyCorp lifted their price objective on shares of Steris from $120.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, November 13th. Zacks Investment Research restated a “buy” rating and set a $132.00 price objective on shares of Steris in a research note on Friday, November 16th. Sidoti lifted their price objective on shares of Steris from $155.00 to $157.00 and gave the company a “buy” rating in a research note on Thursday, December 6th. Finally, JMP Securities restated a “buy” rating and set a $135.00 price objective on shares of Steris in a research note on Thursday, February 14th. Five investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $138.20.

ILLEGAL ACTIVITY WARNING: This report was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://dakotafinancialnews.com/2019/02/20/steris-plc-ste-stake-increased-by-whittier-trust-co-of-nevada-inc.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Recommended Story: How to invest in blue-chip stocks

Institutional Ownership by Quarter for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply